Clinical-stage biopharmaceutical firm Braveheart Bio Inc., which has the backing of venture capital firm Andreessen Horowitz (a16z), filed for an initial public offering on the Nasdaq exchange on Wednesday.

The company, which focuses on developing treatments for cardiovascular diseases, aims to raise an undisclosed amount of capital through the sale of its shares on the Nasdaq Global Market.

Its leading drug candidate is BHB‑1893, currently in development for the treatment of hypertrophic cardiomyopathy.

To date, the company has secured $185 million in funding from investors, including the a16z Bio + Health fund and Patient Square Capital.

Christopher Viehbacher, the Chief Executive Officer of Biogen Inc. (NASDAQ: BIIB), serves as the Chairman of Braveheart's board.

For the first three months of 2026, Braveheart reported a net loss of $14.3 million and generated revenue of approximately $11 million.

This compares to a net loss of $99,000 for the same period in the prior year.

The joint book-running managers for the offering are Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor.

Braveheart will trade on the Nasdaq under the ticker symbol "BRVE".